Pandorum Technologies secures $18 million in Series B funding to advance tissue regenerative therapies. The company plans to use the funds to develop exosome-based treatments, expand globally, and increase manufacturing. Protons Corporate led the funding round, joined by notable investors Galentic Pharma and Ashish Kacholia. Pandorum’s platform targets disease by reprogramming tissue states.